Galectin Therapeutics (NASDAQ:GALT) Director Sells $950,820.00 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Harold Shlevin sold 159,000 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $5.98, for a total transaction of $950,820.00. Following the transaction, the director directly owned 11,206 shares of the company’s stock, valued at approximately $67,011.88. This represents a 93.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Galectin Therapeutics Stock Performance

NASDAQ GALT opened at $6.09 on Wednesday. Galectin Therapeutics Inc. has a twelve month low of $0.73 and a twelve month high of $6.66. The stock has a market capitalization of $392.30 million, a PE ratio of -10.22 and a beta of 0.95. The stock has a 50-day simple moving average of $5.35 and a 200 day simple moving average of $3.95.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities research analysts forecast that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Institutional Trading of Galectin Therapeutics

Large investors have recently bought and sold shares of the stock. HighTower Advisors LLC grew its stake in Galectin Therapeutics by 244.1% during the first quarter. HighTower Advisors LLC now owns 77,375 shares of the company’s stock worth $94,000 after buying an additional 54,889 shares during the last quarter. Wealthspire Advisors LLC raised its holdings in shares of Galectin Therapeutics by 20.4% in the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock valued at $1,012,000 after buying an additional 81,144 shares during the last quarter. Truist Financial Corp bought a new position in shares of Galectin Therapeutics in the second quarter valued at about $143,000. Geneos Wealth Management Inc. lifted its position in Galectin Therapeutics by 8.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after buying an additional 34,300 shares in the last quarter. Finally, Stratos Wealth Partners LTD. grew its holdings in Galectin Therapeutics by 17.8% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company’s stock worth $128,000 after acquiring an additional 9,200 shares during the last quarter. 11.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GALT shares. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Galectin Therapeutics in a report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $6.00.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.